NetworkNewsBreaks – Galectin Therapeutics, Inc. (NASDAQ: GALT) Receives Decision to Grant From Japanese Patent Office for GR-MD-02 Composition of Matter Patent

Galectin Therapeutics (NASDAQ: GALT) this morning said it has received a decision from the Japanese Patent Office to grant its patent application for “Composition of Novel Carbohydrate Drug for Treatment of Human Diseases.” Upon issuance, the patent will expand coverage of the company’s lead compound, GR-MD-02, to Japan through 2032. “The allowance of these claims in Japan further strengthens the protection of the intellectual property behind our proprietary compound, GR-MD-02. This is especially important in Japan, which was recently declared the second most attractive drug market in the world,” Galectin CEO and chief medical officer Peter G. Traber, M.D. stated in the news release.

To view the full press release, visit:

About Galectin Therapeutics

Galectin Therapeutics is developing therapies for the treatment of fibrotic liver disease, skin diseases, and cancer based on the company’s unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at

About NetworkNewsBreak

NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s